173 related articles for article (PubMed ID: 2984249)
1. Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.
Swierkosz EM; Arens MQ; Rivetna KA
J Clin Microbiol; 1985 Mar; 21(3):459-61. PubMed ID: 2984249
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Mayo DR
J Clin Microbiol; 1982 Apr; 15(4):733-6. PubMed ID: 6279696
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
[TBL] [Abstract][Full Text] [Related]
4. Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.
Freeman DJ; Sacks SL; De Clercq E; Spruance SL
Antiviral Res; 1985 Jun; 5(3):169-77. PubMed ID: 2992371
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.
Balzarini J; De Clercq E
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):379-89. PubMed ID: 2545982
[No Abstract] [Full Text] [Related]
6. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
7. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H
Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
9. Serotyping of herpes simplex virus isolates: a comparison of BVDU sensitivities, indirect immunofluorescence with monoclonal antibodies, and indirect immunofluorescence with cross-adsorbed rabbit antibodies.
Sacks SL; Teh CZ; Lemchuk-Favel L
J Virol Methods; 1983 Oct; 7(4):199-206. PubMed ID: 6317706
[TBL] [Abstract][Full Text] [Related]
10. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
11. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.
Balzarini J; Bohman C; De Clercq E
J Biol Chem; 1993 Mar; 268(9):6332-7. PubMed ID: 8384209
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex acyclovir-resistant mutant in experimental keratouveitis.
Boisjoly HM; Park NH; Pavan-Langston D; De Clercq E
Arch Ophthalmol; 1983 Nov; 101(11):1782-6. PubMed ID: 6314952
[TBL] [Abstract][Full Text] [Related]
13. Identification and typing of herpes simplex virus types 1 and 2 by monoclonal antibodies, sensitivity to the drug (E)-5-(2-bromovinyl)-2'-deoxyuridine, and restriction endonuclease analysis of viral DNA.
Zimmerman DH; Mundon FK; Croson SE; Henchal LS; Docherty JJ; O'Neill SP
J Med Virol; 1985 Mar; 15(3):215-22. PubMed ID: 2984324
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine.
Balzarini J; Baumgartner H; Bodenteich M; De Clercq E; Griengl H
J Med Chem; 1989 Aug; 32(8):1861-5. PubMed ID: 2547072
[TBL] [Abstract][Full Text] [Related]
15. Comparison of biological, biochemical, immunological, and immunochemical techniques for typing herpes simplex virus isolates.
Zheng ZM; Mayo DR; Hsiung GD
J Clin Microbiol; 1983 Mar; 17(3):396-9. PubMed ID: 6302130
[TBL] [Abstract][Full Text] [Related]
16. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
Hamel W; Zirkel D; Mehdorn HM; Westphal M; Israel MA
Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
18. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.
Bubley G; Crumpacker C; De Clercq E; Schnipper L
Virology; 1983 Sep; 129(2):490-2. PubMed ID: 6312685
[TBL] [Abstract][Full Text] [Related]
19. Selection of L cell sublines resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Shiraki K; Vonka V; De Clercq E; Rapp F
Intervirology; 1991; 32(4):228-33. PubMed ID: 1650764
[TBL] [Abstract][Full Text] [Related]
20. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents.
Kim JH; Kim SH; Kolozsvary A; Brown SL; Kim OB; Freytag SO
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):861-8. PubMed ID: 7591895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
